CC
TBPH icon

Centiva Capital’s Theravance Biopharma TBPH Stock Holding History

Centiva Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,139
Closed -$103K – 2587
2024
Q2 		$103K Buy
+12,139
New +$110K ﹤0.01% 1846
2022
Q4 		– Sell
-41,300
Closed -$419K – 1617
2022
Q3 		$419K Buy
+41,300
New +$387K 0.01% 931

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Centiva Capital's TBPH Position: Q3 2024 in Review

Centiva Capital sold out of Theravance Biopharma (TBPH) in Q3 2024, closing a stake of 12,139 shares — an estimated $103K sold.

Centiva Capital first reported a position in TBPH in Q3 2022 and held it in 2 quarters. The position peaked at $419K in Q3 2022. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2024.

  • Centiva Capital reported no remaining Theravance Biopharma position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 12,139 Theravance Biopharma shares in Q3 2024, an estimated $103K.
  • Centiva Capital first reported a position in Theravance Biopharma in Q3 2022 and held it in 2 quarters.
  • Centiva Capital's Theravance Biopharma position peaked at $419K in Q3 2022.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.